Exelixis, Inc. (0IJO.L)

USD 33.32

(-9.14%)

Inventory Summary of Exelixis, Inc.

  • Exelixis, Inc.'s latest annual inventory in 2023 was 17.32 Million USD , down -47.98% from previous year.
  • Exelixis, Inc.'s latest quarterly inventory in 2024 Q2 was 20.61 Million USD , down -2.33% from previous quarter.
  • Exelixis, Inc. reported annual inventory of 33.29 Million USD in 2022, up 21.12% from previous year.
  • Exelixis, Inc. reported annual inventory of 27.49 Million USD in 2021, up 31.09% from previous year.
  • Exelixis, Inc. reported quarterly inventory of 21.01 Million USD for 2024 Q3, up 1.94% from previous quarter.
  • Exelixis, Inc. reported quarterly inventory of 21.1 Million USD for 2024 Q1, up 21.84% from previous quarter.

Annual Inventory Chart of Exelixis, Inc. (2023 - 1998)

Historical Annual Inventory of Exelixis, Inc. (2023 - 1998)

Year Inventory Inventory Growth
2023 17.32 Million USD -47.98%
2022 33.29 Million USD 21.12%
2021 27.49 Million USD 31.09%
2020 20.97 Million USD 62.76%
2019 12.88 Million USD 30.98%
2018 9.83 Million USD 47.78%
2017 6.65 Million USD 99.43%
2016 3.33 Million USD 27.6%
2015 2.61 Million USD 9.87%
2014 2.38 Million USD -17.61%
2013 2.89 Million USD 288999900.0%
2012 1.00 USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD -100.0%
2008 13 Thousand USD -74.51%
2007 51 Thousand USD -99.16%
2006 6.08 Million USD 11.76%
2005 5.44 Million USD 0.0%
2004 - USD 0.0%
2003 - USD 0.0%
2002 - USD 0.0%
2001 - USD -100.0%
2000 3.61 Million USD 0.0%
1999 - USD 0.0%
1998 - USD 0.0%

Peer Inventory Comparison of Exelixis, Inc.

Name Inventory Inventory Difference
uniQure N.V. 12.02 Million USD -44.07%
Agios Pharmaceuticals, Inc. 19.07 Million USD 9.19%
Amicus Therapeutics, Inc. 59.69 Million USD 70.981%
Atara Biotherapeutics, Inc. 9.7 Million USD -78.477%
bluebird bio, Inc. 22.91 Million USD 24.416%
Cara Therapeutics, Inc. 2.82 Million USD -514.073%
Imunon, Inc. - USD -Infinity%
Editas Medicine, Inc. - USD -Infinity%
IQVIA Holdings Inc. - USD -Infinity%
Mettler-Toledo International Inc. 385.86 Million USD 95.511%
Myriad Genetics, Inc. 20.1 Million USD 13.816%
Neurocrine Biosciences, Inc. 38.3 Million USD 54.77%
Supernus Pharmaceuticals, Inc. 77.4 Million USD 77.621%
Verastem, Inc. - USD -Infinity%
Walgreens Boots Alliance, Inc. 8.32 Billion USD 99.792%
Waters Corporation 516.23 Million USD 96.644%
Thermo Fisher Scientific Inc. 5.08 Billion USD 99.66%
Biogen Inc. 2.52 Billion USD 99.315%
Nektar Therapeutics 16.1 Million USD -7.59%
Perrigo Company plc 1.14 Billion USD 98.482%
Dynavax Technologies Corporation 53.29 Million USD 67.493%
Illumina, Inc. 587 Million USD 97.049%
Corbus Pharmaceuticals Holdings, Inc. - USD -Infinity%
Iovance Biotherapeutics, Inc. 10.37 Million USD -67.017%
Heron Therapeutics, Inc. 42.11 Million USD 58.863%
Unity Biotechnology, Inc. - USD -Infinity%
BioMarin Pharmaceutical Inc. 1.1 Billion USD 98.435%
Sangamo Therapeutics, Inc. - USD -Infinity%
Evolus, Inc. 10.99 Million USD -57.51%
Adicet Bio, Inc. - USD -Infinity%
Aclaris Therapeutics, Inc. - USD -Infinity%
Regeneron Pharmaceuticals, Inc. 2.58 Billion USD 99.329%
Esperion Therapeutics, Inc. 65.62 Million USD 73.602%
FibroGen, Inc. 41.56 Million USD 58.323%
Agilent Technologies, Inc. 1.03 Billion USD 98.32%
OPKO Health, Inc. 65.69 Million USD 73.632%
Homology Medicines, Inc. - USD -Infinity%
Geron Corporation - USD -Infinity%
Alnylam Pharmaceuticals, Inc. 89.14 Million USD 80.568%
Viking Therapeutics, Inc. - USD -Infinity%
Anavex Life Sciences Corp. - USD -Infinity%
Intellia Therapeutics, Inc. - USD -Infinity%
Zoetis Inc. 2.56 Billion USD 99.324%
Axsome Therapeutics, Inc. 15.13 Million USD -14.457%
Abeona Therapeutics Inc. -2.44 Million USD 808.797%
Vertex Pharmaceuticals Incorporated 738.8 Million USD 97.655%
Kala Pharmaceuticals, Inc. - USD -Infinity%
Ionis Pharmaceuticals, Inc. 28.42 Million USD 39.057%
Sarepta Therapeutics, Inc. 322.85 Million USD 94.634%
Corcept Therapeutics Incorporated 7.73 Million USD -124.101%
Halozyme Therapeutics, Inc. 127.6 Million USD 86.424%
Blueprint Medicines Corporation 21.22 Million USD 18.376%
Insmed Incorporated 83.24 Million USD 79.191%
TG Therapeutics, Inc. 39.82 Million USD 56.5%
Incyte Corporation 62.97 Million USD 72.491%
Emergent BioSolutions Inc. 328.9 Million USD 94.733%